Profile data is unavailable for this security.
About the company
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
- Revenue in USD (TTM)0.00
- Net income in USD-67.51m
- Incorporated2013
- Employees28.00
- LocationCorbus Pharmaceuticals Holdings Inc500 River Ridge DriveNORWOOD 02062United StatesUSA
- Phone+1 (617) 963-0103
- Websitehttps://www.corbuspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiff Oncology Inc | 593.00k | -45.88m | 132.63m | 31.00 | -- | 2.92 | -- | 223.66 | -0.6873 | -0.6873 | 0.0089 | 0.6645 | 0.0075 | -- | 1.24 | 19,129.03 | -57.65 | -36.79 | -70.95 | -40.48 | -- | -- | -7,732.04 | -7,960.06 | -- | -- | 0.00 | -- | -13.18 | 10.13 | -0.9262 | -- | -26.97 | -- |
| Oramed Pharmaceuticals, Inc. | 2.00m | 43.85m | 132.94m | 13.00 | 3.32 | 0.671 | 3.03 | 66.47 | 1.01 | 1.01 | 0.0478 | 4.98 | 0.0104 | -- | -- | 153,846.20 | 22.72 | -- | 23.30 | -- | 0.65 | -- | 2,190.40 | -- | -- | -- | 0.00 | -- | -100.00 | -- | -444.98 | -- | -- | -- |
| Polaryx Therapeutics, Inc | -100.00bn | -100.00bn | 136.35m | 2.00 | -- | 25.72 | -- | -- | -- | -- | -- | 0.112 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -703.28 | -- | -- | -- |
| Immunic Inc | 0.00 | -97.17m | 138.29m | 92.00 | -- | -- | -- | -- | -0.6855 | -0.6855 | 0.00 | -0.0554 | 0.00 | -- | -- | 0.00 | -299.36 | -110.19 | -1,602.57 | -137.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.32 | -- | 1.98 | -- |
| Black Diamond Therapeutics Inc | 70.00m | 21.50m | 138.45m | 24.00 | 6.70 | 1.10 | 6.34 | 1.98 | 0.3629 | 0.3629 | 1.23 | 2.22 | 0.4736 | -- | -- | 2,916,667.00 | 14.54 | -42.24 | 16.58 | -46.05 | -- | -- | 30.71 | -- | -- | -- | 0.00 | -- | -- | -- | 15.48 | -- | -- | -- |
| Connect Biopharma Holdings Ltd (ADR) | 762.00k | -50.77m | 139.76m | 62.00 | -- | 2.52 | -- | 183.41 | -0.9144 | -0.9144 | 0.0137 | 0.9926 | -- | -- | -- | 12,290.32 | -- | -61.12 | -- | -66.78 | -- | -- | -6,662.99 | -1,963.00 | -- | -- | 0.00 | -- | -- | -- | 74.84 | -- | 37.04 | -- |
| vTv Therapeutics Inc | 17.00k | -23.47m | 140.20m | 23.00 | -- | 1.99 | -- | 8,247.18 | -3.32 | -3.32 | 0.0024 | 17.91 | 0.0002 | -- | -- | 739.13 | -39.79 | -96.30 | -46.08 | -- | -- | -- | -166,935.30 | -775.06 | -- | -- | 0.0046 | -- | -- | -18.12 | 8.83 | -- | -- | -- |
| Artiva Biotherapeutics Inc | 0.00 | -79.19m | 141.62m | 106.00 | -- | 1.10 | -- | -- | -3.25 | -3.25 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -42.29 | -44.57 | -45.24 | -51.09 | -- | -- | -- | -596.66 | -- | -- | 0.0006 | -- | -99.25 | -- | -127.62 | -- | 18.74 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -67.51m | 146.57m | 28.00 | -- | 1.14 | -- | -- | -5.51 | -5.51 | 0.00 | 7.35 | 0.00 | -- | -- | 0.00 | -49.34 | -69.78 | -55.11 | -97.84 | -- | -- | -- | -5,894.85 | -- | -- | 0.00 | -- | -- | -- | 9.85 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -58.01m | 147.34m | 33.00 | -- | 7.19 | -- | -- | -0.8938 | -0.8938 | 0.00 | 0.2407 | 0.00 | -- | -- | 0.00 | -68.07 | -48.63 | -75.01 | -52.10 | -- | -- | -- | -1,201.96 | -- | -73.28 | 0.7327 | -- | -100.00 | -- | 30.44 | -- | -39.67 | -- |
| Unicycive Therapeutics Inc | 0.00 | -33.47m | 150.22m | 22.00 | -- | 3.89 | -- | -- | -2.85 | -2.85 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -74.93 | -188.44 | -101.88 | -723.53 | -- | -- | -- | -6,003.20 | -- | -- | 0.00 | -- | -100.00 | -- | -20.42 | -- | -- | -- |
| Sangamo Therapeutics Inc | 32.88m | -108.91m | 153.56m | 183.00 | -- | 22.17 | -- | 4.67 | -0.4428 | -0.4428 | 0.1326 | 0.0194 | 0.3289 | -- | 5.97 | 179,644.80 | -108.96 | -30.73 | -204.29 | -37.33 | -- | -- | -331.28 | -147.59 | -- | -- | 0.00 | -- | -67.20 | -10.81 | 62.01 | -- | -58.10 | -- |
| AVITA Medical Inc | 71.61m | -48.59m | 161.43m | 226.00 | -- | -- | -- | 2.25 | -1.75 | -1.75 | 2.57 | -0.5446 | 1.05 | 1.69 | 6.86 | 316,854.00 | -71.40 | -- | -182.42 | -- | 83.27 | -- | -67.85 | -- | 0.4557 | -8.22 | 1.63 | -- | 11.45 | -- | 21.44 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Corbus Pharmaceuticals Holdings Inc's reporting currency: US Dollar USD
49.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cormorant Asset Management LPas of 31 Dec 2025 | 2.34m | 13.36% |
| abrdn, Inc.as of 31 Dec 2025 | 1.32m | 7.53% |
| Octagon Capital Advisors LPas of 31 Dec 2025 | 955.00k | 5.44% |
| Citadel Advisors LLCas of 31 Dec 2025 | 843.19k | 4.80% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 758.47k | 4.32% |
| Prosight Management LPas of 31 Dec 2025 | 683.87k | 3.90% |
| OrbiMed Advisors LLCas of 31 Jan 2026 | 538.60k | 3.07% |
| Armistice Capital LLCas of 31 Dec 2025 | 536.00k | 3.05% |
| Stonepine Capital Management LLCas of 31 Dec 2025 | 389.92k | 2.22% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 354.30k | 2.02% |
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
